Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL

February 24th 2025

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML

February 24th 2025

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

FDA Accepts sBLA for Nivolumab/Ipilimumab in Unresectable/Metastatic MSI-H/dMMR CRC

February 24th 2025

The combination of nivolumab and ipilimumab is under priority review for the frontline treatment of patients with unresectable/metastatic MSI-H/dMMR CRC.

Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions

February 20th 2025

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.

Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL

February 20th 2025

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm

February 19th 2025

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases

February 19th 2025

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma

February 18th 2025

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

FDA Grants Priority Review to Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

February 18th 2025

The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.

Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC

February 15th 2025

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Real-World Data Support the Frontline Use of Avelumab Plus Axitinib in Advanced RCC

February 15th 2025

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL

February 14th 2025

MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.

UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC

February 14th 2025

UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.

Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC

February 14th 2025

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

Precise Targets and Drug Sequencing Potential Characterize the State of ADCs in Ovarian Cancer

February 11th 2025

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL

February 7th 2025

Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.

Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia

February 7th 2025

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

ATG-022 Demonstrates Safety, Preliminary Efficacy in Advanced CLDN18.2+ Gastric Cancer

February 6th 2025

Phase 1 study data demonstrated that ATG-022 has a manageable safety profile and produced activity in patients with gastric cancer and CLDN 18.2 expressions.

Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML

February 6th 2025

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

FDA Grants Orphan Drug Designation to 225Ac-Satoreotide for SCLC

February 6th 2025

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.